Preserved functional autonomic phenotype in adult mice overexpressing moderate levels of human alpha-synuclein in oligodendrocytes

Physiological Reports

Volumn 2, Issue 11, 2014, Pages

  Tank, Jens ^a   da Costa Goncalves, Andrey C ^b   Kamer, Ilona ^b   Qadri, Fatimunnisa ^b   Ubhi, Kiren ^c   Rockenstein, Edward ^c   Diedrich, André ^d   Masliah, Eliezer ^c   Gross, Volkmar ^b   Jordan, Jens ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Autonomic failure; Blood pressure; Human alpha synuclein; Multiple system atrophy; Transgenic mice

Indexed keywords

ALPHA SYNUCLEIN; ATROPINE; CLONIDINE; METOPROLOL; TRIMETAPHAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE VARIABILITY; CIRCADIAN RHYTHM; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; GENE OVEREXPRESSION; HEART RHYTHM; HISTOCHEMISTRY; MEAN ARTERIAL PRESSURE; MOUSE; NONHUMAN; OLIGODENDROGLIA; PHENOTYPE; SHY DRAGER SYNDROME; SYSTOLIC BLOOD PRESSURE; TELEMETRY;

EID: 85003530551     PISSN: None     EISSN: 2051817X     Source Type: Journal    
DOI: 10.14814/phy2.12209     Document Type: Article

References (21)

1. Flabeau, O., W. G. Meissner, and F. Tison. 2010. Multiple system atrophy: current and future approaches to management. Ther. Adv. Neurol. Disord. 3:249-263.
2. Fleming, S. M., M. C. Jordan, C. K. Mulligan, E. Masliah, J. G. Holden, R. W. Millard, et al. 2013. Impaired baroreflex function in mice overexpressing alpha-synuclein. Front. Neurol. 4:103.
3. Gilman, S., G. K. Wenning, P. A. Low, D. J. Brooks, C. J. Mathias, J. Q. Trojanowski, et al. 2008. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 71:670-676.
4. Gross, V., J. Tank, H. J. Partke, R. Plehm, A. Diedrich, A. C. da Costa Goncalves, et al. 2008. Cardiovascular autonomic regulation in Non-Obese Diabetic (NOD) mice. Auton. Neurosci. 138:108-113.
5. Kahle, P. J., M. Neumann, L. Ozmen, V. Muller, H. Jacobsen, W. Spooren, et al. 2002. Hyperphosphorylation and insolubility of alpha-synuclein in transgenic mouse oligodendrocytes. EMBO Rep. 3:583-588.
6. Kaufmann, H., and I. Biaggioni. 2003. Autonomic failure in neurodegenerative disorders. Semin. Neurol. 23:351-363.
7. Kuzdas, D., S. Stemberger, S. Gaburro, N. Stefanova, N. Singewald, and G. K. Wenning. 2013. Oligodendroglial alpha-synucleinopathy and MSA-like cardiovascular autonomic failure: experimental evidence. Exp. Neurol. 247:531-536.
8. Polinsky, R. J. 1984. Multiple system atrophy. Clinical aspects, pathophysiology, and treatment. Neurol. Clin. 2:487-498.
9. Robertson, D., J. R. Shannon, J. Jordan, T. L. Davis, A. Diedrich, G. Jacob, et al. 2001. Multiple system atrophy: new developments in pathophysiology and therapy. Parkinsonism Relat. Disord. 7:257-260.
10. Rockenstein, E., L. Crews, and E. Masliah. 2007. Transgenic animal models of neurodegenerative diseases and their application to treatment development. Adv. Drug Deliv. Rev. 59:1093-1102.
11. Sharabi, Y., B. Eldadah, S. T. Li, R. Dendi, S. Pechnik, C. Holmes, et al. 2006. Neuropharmacologic distinction of neurogenic orthostatic hypotension syndromes. Clin. Neuropharmacol. 29:97-105.
12. Shults, C. W., E. Rockenstein, L. Crews, A. Adame, M. Mante, G. Larrea, et al. 2005. Neurological and neurodegenerative alterations in a transgenic mouse model expressing human alpha-synuclein under oligodendrocyte promoter: implications for multiple system atrophy. J. Neurosci. 25:10689-10699.
13. Stefanova, N., F. Tison, M. Reindl, W. Poewe, and G. K. Wenning. 2005. Animal models of multiple system atrophy. Trends Neurosci. 28:501-506.
14. Stefanova, N., M. Hainzer, S. Stemberger, S. Couillard-Despres, L. Aigner, W. Poewe, et al. 2009. Striatal transplantation for multiple system atrophy-are grafts affected by alpha-synucleinopathy? Exp. Neurol. 219:368-371.
15. Stemberger, S., A. Jamnig, N. Stefanova, G. Lepperdinger, M. Reindl, and G. K. Wenning. 2011. Mesenchymal stem cells in a transgenic mouse model of multiple system atrophy: immunomodulation and neuroprotection. PLoS ONE 6:e19808.
16. Ubhi, K., E. Rockenstein, M. Mante, C. Patrick, A. Adame, M. Thukral, et al. 2008. Rifampicin reduces alpha-synuclein in a transgenic mouse model of multiple system atrophy. NeuroReport 19:1271-1276.
17. Ubhi, K., E. Rockenstein, M. Mante, C. Inglis, A. Adame, C. Patrick, et al. 2010. Neurodegeneration in a transgenic mouse model of multiple system atrophy is associated with altered expression of oligodendroglial-derived neurotrophic factors. J. Neurosci. 30:6236-6246.
18. Ubhi, K., P. Low, and E. Masliah. 2011. Multiple system atrophy: a clinical and neuropathological perspective. Trends Neurosci. 34:581-590.
19. Ubhi, K., E. Rockenstein, R. Vazquez-Roque, M. Mante, C. Inglis, C. Patrick, et al. 2013. Cerebrolysin modulates pronerve growth factor/nerve growth factor ratio and ameliorates the cholinergic deficit in a transgenic model of Alzheimer’s disease. J. Neurosci. Res. 91:167-177.
20. Usera, P. C., S. Vincent, and D. Robertson. 2004. Human phenotypes and animal knockout models of genetic autonomic disorders. J. Biomed. Sci. 11:4-10.
21. Yazawa, I., B. I. Giasson, R. Sasaki, B. Zhang, S. Joyce, K. Uryu, et al. 2005. Mouse model of multiple system atrophy alpha-synuclein expression in oligodendrocytes causes glial and neuronal degeneration. Neuron 45:847-859.